Halozyme Therapeutics (HALO) Stock Price
Halozyme Therapeutics Price
Over the last 19 years Halozyme Therapeutics grew revenue by 46.5% annually, reaching 1.40 B USD. Earnings per share have grown at 25.7% per year over the last 8 years. For Halozyme Therapeutics, the net margin of 22.7% is down versus 90.8% a few years ago. The consensus 12-month price target for Halozyme Therapeutics is 105.00 USD, about 1.3% above where the stock trades today. Of 16 analysts, 13 rate the stock a buy — an overall Buy consensus.
Halozyme Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Halozyme Therapeutics business model & stock analysis
Frequently asked questions about Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative treatments for patients with cancer, immune disorders, and other serious diseases. The company's business model revolves around its proprietary ENHANZE® drug delivery technology platform, which enables the subcutaneous administration of biologics by targeting the body's extracellular matrix. This approach offers numerous benefits, including reduced treatment times and improved convenience for patients, as well as potential cost savings for healthcare systems. Halozyme partners with leading pharmaceutical companies to apply its technology to a wide range of therapeutic areas, aiming to improve treatment options and ultimately enhance patients' lives.
Halozyme Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Halozyme Therapeutics Inc in the market are Bristol-Myers Squibb, Roche Holdings AG, and Johnson & Johnson.
Halozyme Therapeutics Inc. is a biotechnology company founded in 1998. Based in San Diego, California, the company develops and commercializes innovative drug therapies for various diseases. Halozyme specializes in enzyme-based technologies that enable the subcutaneous delivery of injectable drugs. Their proprietary platform, Enhanze®, enables the dispersion and absorption of drugs that are typically administered intravenously. Through partnerships and collaborations with pharmaceutical and biotech companies, Halozyme has advanced the development of several therapeutic products. With a focus on enhancing treatment options, Halozyme Therapeutics Inc. continues to make significant contributions to the field of biotechnology.
Halozyme Therapeutics Inc has achieved significant milestones throughout its history. Some of the notable achievements include the FDA approval of its Enhanze® drug delivery technology platform, which enables the subcutaneous administration of therapies that were previously only available intravenously. This innovative technology has been licensed to various renowned pharmaceutical companies, leading to successful collaborations and clinical advancements. Additionally, Halozyme has successfully developed and commercialized multiple products, such as Herceptin® SC and Hylenex®, providing patients with improved treatment options. With its continuous focus on research and development, Halozyme Therapeutics Inc remains committed to driving innovation in the field of drug delivery and enhancing patients' lives.
Halozyme Therapeutics Inc primarily operates in the United States.
Halozyme Therapeutics Inc is a biotechnology company that is focused on developing and commercializing innovative cancer treatments. The company's values revolve around the commitment to improving patient outcomes and transforming the way cancer is treated. Halozyme aims to provide innovative therapies that are more effective, less invasive, and more accessible to patients worldwide. Their corporate philosophy is rooted in collaboration, continuous innovation, and patient-centricity. By working together with physicians, researchers, and partners, Halozyme strives to create novel solutions that address unmet medical needs and make a positive impact on the lives of cancer patients.
Analysts currently set an average price target of 103.00 USD for the Halozyme Therapeutics stock (median: 105.00 USD), implying -0.6 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Halozyme Therapeutics stock: 13 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Halozyme Therapeutics to generate revenue of 1.88 B USD and earnings per share of 8.61 USD.
Converted at the current exchange rate, the Halozyme Therapeutics share trades at 92.95 EUR (103.63 USD).
The Halozyme Therapeutics share (HALO) is listed on 7 stock exchanges, including: NASDAQ (HALO), London (0J2O.L), SIX (Zürich) (RV7.SW), Frankfurt (RV7.F), München (RV7.MU), Düsseldorf (RV7.DU).
Halozyme Therapeutics Inc is a biopharmaceutical company based in San Diego, California. The company specializes in the development and commercialization of enzyme technology platforms used in the treatment of cancer and other serious diseases. Their main business model is focused on improving pharmaceutical drug delivery through the development and marketing of enzyme technology platforms. These technology platforms enable the administration of therapeutic proteins and other drugs at higher concentrations and for longer periods of time. Halozyme offers several products based on their technology platforms, including PEGPH20, an enzyme used in the treatment of pancreatic cancer. PEGPH20 helps shrink tumors and increase tumor blood flow to allow for more effective treatment. Halozyme Therapeutics also provides enzymes like hyaluronidase, which help break through the blood-brain barrier, allowing for better absorption of medications and other drugs into the brain. This can be of great advantage in treating neurological diseases such as Alzheimer's and Parkinson's. Another product from Halozyme is their Enhanze enzyme technology platform, which enables the administration of therapeutic proteins at higher concentrations and for longer periods of time. This technology has the potential to improve the treatment of chronic diseases like arthritis and blood disorders. Additionally, Halozyme Therapeutics collaborates closely with other pharmaceutical companies to integrate their technology platforms into their product development. This allows the company to benefit from licensing revenues and milestone payments resulting from these partnerships. Another business model of Halozyme Therapeutics is the development of biosimilars. Biosimilars are replicas of biopharmaceutical drugs that are already available on the market. These drugs are typically more cost-effective than the original products and can help improve access to life-saving medications. Halozyme Therapeutics has partnered with a major pharmaceutical company to develop biosimilars for several drugs. The company's enzyme technology platforms enable the improvement of efficacy and safety of these biosimilars, which can contribute to faster regulatory approval. Overall, Halozyme Therapeutics has developed a diverse business model based on the development and commercialization of enzyme technology platforms. Through collaboration with other pharmaceutical companies, the company can increase its market share and expand the application of its technology platforms to new areas.
The expected revenue of Halozyme Therapeutics is 1.88 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Halozyme Therapeutics is 1.01 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Halozyme Therapeutics is currently 12.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Halozyme Therapeutics stock.
The price-to-sales ratio (P/S) of Halozyme Therapeutics is currently 6.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Halozyme Therapeutics stock.
The Eulerpool Quality Score for Halozyme Therapeutics is 8/10.
The ISIN of Halozyme Therapeutics is US40637H1095. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Halozyme Therapeutics is A0DLHS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Halozyme Therapeutics is HALO. The ticker symbol is used to trade Halozyme Therapeutics shares on the stock exchange.
Halozyme Therapeutics stock
Halozyme Therapeutics Peer Group
Halozyme Therapeutics Ticker
Halozyme Therapeutics FIGI
All fundamentals and in-depth analysis of Halozyme Therapeutics
Our stock analysis for Halozyme Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Halozyme Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.